1] Institute of Head and Neck Studies and Education (InHANSE), School of Cancer Sciences, University of Birmingham, Birmingham B15 2TT, UK [2] Department of Otolaryngology, University Hospital Coventry and Warwickshire, Coventry CV2 2DX, UK [3] Department of Otolaryngology, University Hospital Birmingham, Birmingham B15 2WB, UK.
Br J Cancer. 2013 Nov 26;109(11):2864-74. doi: 10.1038/bjc.2013.600. Epub 2013 Nov 7.
Prognostic biomarkers aim to improve on the current inadequate method of histological assessment to identify patients with oral epithelial dysplasia at greatest risk of malignant transformation. We aimed to assess the prognostic ability of six protein biomarkers linked to the epidermal growth factor receptor (EGFR) pathway, including three tetraspanins, in a large multicentre oral dysplasia cohort.
One hundred and forty-eight cases with varying degrees of epithelial dysplasia underwent immunohistochemical assessment for CD9, CD151, CD82, EGFR, Her-2, and COX-2. Scoring was performed independently by two observers. Univariate analyses using both logistic and Cox regression models and a multivariate regression were performed.
Malignant progression was significantly greater in those cases with decreased expression of CD9 (P=0.02), and increased expression of CD151 (P=0.02), EGFR (P=0.04), and COX-2 (P=0.003). Histological grade (P=0.0002) and morphology (P=0.03) were also prognostic, whereas smoking and alcohol were not. The optimal combination by backward-variable selection was of histological grade (hazard ratio (HR) 1.64; 95% CI 1.12, 2.40), COX-2 overexpression (HR 1.12; 1.02, 1.24) and CD9 underexpression (HR 0.88; 0.80, 0.97). CD82 and Her-2 demonstrated no prognostic ability.
This is the first study of the expression and prognostic potential of the tetraspanins in oral dysplasia. A combination of certain biomarkers with clinical factors appeared to improve the accuracy of determining the risk of malignancy in individuals with oral dysplasia. These findings may also offer potential new therapeutic approaches for this condition.
预后生物标志物旨在改进目前对口腔上皮异型增生进行组织学评估的不足方法,以确定恶性转化风险最高的患者。我们旨在评估与表皮生长因子受体(EGFR)途径相关的六种蛋白生物标志物(包括三种四跨膜蛋白)在大型多中心口腔异型增生队列中的预后能力。
148 例不同程度上皮异型增生患者接受 CD9、CD151、CD82、EGFR、Her-2 和 COX-2 的免疫组织化学评估。由两位观察者独立进行评分。使用逻辑和 Cox 回归模型进行单变量分析,以及多变量回归。
CD9 表达降低(P=0.02)和 CD151(P=0.02)、EGFR(P=0.04)和 COX-2(P=0.003)表达增加的病例恶性进展显著增加。组织学分级(P=0.0002)和形态(P=0.03)也是预后因素,而吸烟和饮酒则不是。通过向后变量选择的最佳组合是组织学分级(危险比(HR)1.64;95%置信区间 1.12,2.40)、COX-2 过表达(HR 1.12;1.02,1.24)和 CD9 表达降低(HR 0.88;0.80,0.97)。CD82 和 Her-2 没有显示出预后能力。
这是首次研究四跨膜蛋白在口腔异型增生中的表达和预后潜力。某些生物标志物与临床因素的结合似乎可以提高确定口腔异型增生个体恶性转化风险的准确性。这些发现也可能为该疾病提供新的潜在治疗方法。